![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: KCNT2 |
Gene summary for KCNT2 |
![]() |
Gene information | Species | Human | Gene symbol | KCNT2 | Gene ID | 343450 |
Gene name | potassium sodium-activated channel subfamily T member 2 | |
Gene Alias | DEE57 | |
Cytomap | 1q31.3 | |
Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | Q6UVM3 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
343450 | KCNT2 | NAFLD1 | Human | Liver | NAFLD | 8.49e-19 | 1.15e+00 | -0.04 |
343450 | KCNT2 | S41 | Human | Liver | Cirrhotic | 3.93e-05 | 6.02e-01 | -0.0343 |
343450 | KCNT2 | HCC1_Meng | Human | Liver | HCC | 5.82e-57 | -1.87e-01 | 0.0246 |
343450 | KCNT2 | HCC2_Meng | Human | Liver | HCC | 1.22e-08 | -3.36e-01 | 0.0107 |
343450 | KCNT2 | cirrhotic1 | Human | Liver | Cirrhotic | 2.20e-10 | -3.33e-01 | 0.0202 |
343450 | KCNT2 | cirrhotic2 | Human | Liver | Cirrhotic | 1.30e-08 | -3.26e-01 | 0.0201 |
343450 | KCNT2 | HCC1 | Human | Liver | HCC | 9.91e-07 | -1.48e-01 | 0.5336 |
343450 | KCNT2 | Pt13.a | Human | Liver | HCC | 1.85e-08 | -3.27e-01 | 0.021 |
343450 | KCNT2 | Pt14.d | Human | Liver | HCC | 3.67e-06 | -2.90e-01 | 0.0143 |
343450 | KCNT2 | S016 | Human | Liver | HCC | 1.56e-02 | -3.38e-01 | 0.2243 |
343450 | KCNT2 | S027 | Human | Liver | HCC | 2.52e-05 | 2.47e-01 | 0.2446 |
343450 | KCNT2 | S028 | Human | Liver | HCC | 1.89e-13 | 2.18e-01 | 0.2503 |
343450 | KCNT2 | S029 | Human | Liver | HCC | 2.82e-05 | 8.78e-02 | 0.2581 |
343450 | KCNT2 | HTA12-15-2 | Human | Pancreas | PDAC | 3.40e-10 | 7.20e-01 | 0.2315 |
343450 | KCNT2 | HTA12-23-1 | Human | Pancreas | PDAC | 7.37e-16 | 1.21e+00 | 0.3405 |
343450 | KCNT2 | HTA12-25-1 | Human | Pancreas | PDAC | 3.74e-18 | 1.23e+00 | 0.313 |
343450 | KCNT2 | HTA12-26-1 | Human | Pancreas | PDAC | 2.52e-36 | 1.47e+00 | 0.3728 |
343450 | KCNT2 | HTA12-29-1 | Human | Pancreas | PDAC | 1.41e-72 | 1.55e+00 | 0.3722 |
343450 | KCNT2 | HTA12-30-1 | Human | Pancreas | PDAC | 5.66e-08 | 1.45e+00 | 0.3671 |
343450 | KCNT2 | HTA12-32-1 | Human | Pancreas | PDAC | 4.23e-05 | 9.72e-01 | 0.3624 |
Page: 1 2 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
KCNT2 | SNV | Missense_Mutation | c.3188N>C | p.Leu1063Ser | p.L1063S | Q6UVM3 | protein_coding | deleterious(0.01) | probably_damaging(0.973) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
KCNT2 | SNV | Missense_Mutation | c.1600N>G | p.Ile534Val | p.I534V | Q6UVM3 | protein_coding | tolerated(0.09) | possibly_damaging(0.473) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
KCNT2 | SNV | Missense_Mutation | c.823G>A | p.Glu275Lys | p.E275K | Q6UVM3 | protein_coding | deleterious(0) | probably_damaging(0.962) | TCGA-AP-A0LD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
KCNT2 | SNV | Missense_Mutation | c.3038N>C | p.Lys1013Thr | p.K1013T | Q6UVM3 | protein_coding | deleterious(0.01) | possibly_damaging(0.597) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
KCNT2 | SNV | Missense_Mutation | c.55N>T | p.Asp19Tyr | p.D19Y | Q6UVM3 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.813) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
KCNT2 | SNV | Missense_Mutation | novel | c.1249N>C | p.Val417Leu | p.V417L | Q6UVM3 | protein_coding | deleterious(0.04) | possibly_damaging(0.814) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
KCNT2 | SNV | Missense_Mutation | novel | c.963N>A | p.Phe321Leu | p.F321L | Q6UVM3 | protein_coding | deleterious(0) | probably_damaging(0.966) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
KCNT2 | SNV | Missense_Mutation | novel | c.2827C>T | p.Leu943Phe | p.L943F | Q6UVM3 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-AP-A1E0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
KCNT2 | SNV | Missense_Mutation | novel | c.2773C>A | p.Leu925Ile | p.L925I | Q6UVM3 | protein_coding | deleterious(0) | probably_damaging(0.927) | TCGA-AP-A1E0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
KCNT2 | SNV | Missense_Mutation | novel | c.2283N>A | p.Asp761Glu | p.D761E | Q6UVM3 | protein_coding | tolerated(0.21) | benign(0.005) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
343450 | KCNT2 | ION CHANNEL, DRUGGABLE GENOME | blocker | 135651249 | ||
343450 | KCNT2 | ION CHANNEL, DRUGGABLE GENOME | activator | 135650269 | ||
343450 | KCNT2 | ION CHANNEL, DRUGGABLE GENOME | blocker | 53801073 | CLOFILIUM | |
343450 | KCNT2 | ION CHANNEL, DRUGGABLE GENOME | inhibitor | 135650820 | ||
343450 | KCNT2 | ION CHANNEL, DRUGGABLE GENOME | phorbol 12-myristate 13-acetate | |||
343450 | KCNT2 | ION CHANNEL, DRUGGABLE GENOME | Bisphosphonates | |||
343450 | KCNT2 | ION CHANNEL, DRUGGABLE GENOME | blocker | 135652729 | ||
343450 | KCNT2 | ION CHANNEL, DRUGGABLE GENOME | activator | 135650716 |
Page: 1 |